A major determinant of the immunogenicity of factor VIII in a murine model is independent of its procoagulant function

Blood

Volumn 120, Issue 12, 2012, Pages 2512-2520

  Meeks, Shannon L ^a   Cox, Courtney L ^a   Healey, John F ^a   Parker, Ernest T ^a   Doshi, Bhavya S ^a   Gangadharan, Bagirath ^a   Barrow, Rachel T ^a   Lollar, Pete ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; VON WILLEBRAND FACTOR;

ARTICLE; FEMALE; HEMOPHILIA A; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION;

EID: 84866623741     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-02-412361     Document Type: Article

References (47)

1. Lusher JM, Arkin S, Abildgaard CF, Schwartz RS, and the Kogenate Previously Untreated Patient Study Group. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and the development of inhibitors. N Engl J Med. 1993;328(7):453-459.
2. Lollar P. Pathogenic antibodies to coagulation factors, I: factor VIII and factor IX. J Thromb Haemost. 2004;2(7):1082-1095.
3. Schwartz RH. T cell anergy. Sci Am. 1993;269(2):62-71.
4. Skupsky J, Zhang AH, Su Y, Scott DW. A role for thrombin in the initiation of the immune response to therapeutic factor VIII. Blood. 2009;114(21):4741-4748.
5. Janeway CA Jr. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb Symp Quant Biol. 1989;54(Pt 1):1-13.
6. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol. 1994;12:991-1045.
7. Esmon CT. Interactions between the innate immune and blood coagulation systems. Trends Immunol. 2004;25(10):536-542.
8. McGinniss MJ, Kazazian HH Jr, Hoyer LW, Bi L, Inaba H, Antonarakis SE. Spectrum of mutations in CRM-positive and CRM-reduced hemophilia A. Genomics. 1993;15(2):392-398.
9. Lind P, Larsson K, Spira J, et al. Novel forms of B-domain-deleted recombinant factor VIII molecules. Construction and biochemical characterization. Eur J Biochem. 1995;232(1):19-27.
10. Healey JF, Barrow RT, Tamim HM, et al. Residues Glu2181-Val2243 contain a major determinant of the inhibitory epitope in the C2 domain of human factor VIII. Blood. 1998;92(10):3701-3709.
11. Summers RJ, Meeks SL, Healey JF, et al. Factor VIII A3 domain substitution N1922S results in hemophilia A due to domain-specific misfolding and hyposecretion of functional protein. Blood. 2011;117(11):3190-3198.
12. Doering CB, Healey JF, Parker ET, Barrow RT, Lollar P. High-level expression of recombinant porcine coagulation factor VIII. J Biol Chem. 2002;277(41):38345-38349.
13. Meeks SL, Healey JF, Parker ET, Barrow RT, Lollar P. Anti-human factor VIII C2 domain antibodies in hemophilia A mice recognize a functionally complex continuous spectrum of epitopes dominated by inhibitors of factor VIII activation. Blood. 2007;110(13):4234-4242.
14. Doering CB, Parker ET, Healey JF, Craddock HN, Barrow RT, Lollar P. Expression and characterization of recombinant murine factor VIII. Thromb Haemost. 2002;88(3):450-458.
15. Parker ET, Doering CB, Lollar P. A1 subunit-mediated regulation of thrombin-activated factor VIII A2 subunit dissociation. J Biol Chem. 2006;281(20):13922-13930.
16. Duffy EJ, Lollar P. Intrinsic pathway activation of factor X and its activation peptide-deficient derivative, factor X(Des 143-191). J Biol Chem. 1992;267(11):7821-7827.
17. Bi L, Lawler AM, Antonarakis SE, High KA, Gearhart JD, Kazazian HH Jr. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Nat Genet. 1995;10(1):119-121.
18. Bi L, Sarkar R, Naas T, et al. Further characterization of factor VIII-deficient mice created by gene targeting: RNA and protein studies. Blood. 1996;88(9):3446-3450.
19. Denis C, Methia N, Frenette PS, et al. A mouse model of severe von Willebrand disease: defects in hemostasis and thrombosis. Proc Natl Acad Sci U S A. 1998;95(16):9524-9529.
20. Meeks SL, Healey JF, Parker ET, Barrow RT, Lollar P. Non-classical anti-C2 domain antibodies are present in patients with factor VIII inhibitors. Blood. 2008;112(4):1151-1153.
21. Kasper CK, Aledort LM, Counts RB, et al. A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh. 1975;34(3):869-872.
22. Barrow RT, Lollar P. Neutralization of anti-factor VIII inhibitors by recombinant porcine factor VIII. J Thromb Haemost. 2006;4(10):2223-2229.
23. Lollar P, Hill-Eubanks DC, Parker CG. Association of the factor VIII light chain with von Willebrand factor. J Biol Chem. 1988;263(21):10451-10455.
24. Healey JF, Lubin IM, Nakai H, et al. Residues 484-508 contain a major determinant of the inhibitory epitope in the A2 domain of human factor VIII. J Biol Chem. 1995;270(24):14505-14509.
25. Healey JF, Parker ET, Barrow RT, Langley TJ, Church WR, Lollar P. The humoral response to human factor VIII in hemophilia A mice. J Thromb Haemost. 2007;5(3):512-517.
26. Dasgupta S, Navarrete AM, Bayry J, et al. A role for exposed mannosylations in presentation of human therapeutic self-proteins to CD4+ T lymphocytes. Proc Natl Acad Sci U S A. 2007;104(21):8965-8970.
27. Herczenik E, van Haren SD, Wroblewka A, et al. Uptake of blood coagulation factor VIII by dendritic cells is mediated via its C1 domain. J Allergy Clin Immunol. 2012;129(2):501-509.
28. Meems H, van den Biggelaar M, Rondaij M, van der Zwaan C, Mertens K, Meijer AB. C1 domain residues Lys 2092 and Phe 2093 are of major importance for the endocytic uptake of coagulation factor VIII. Int J Biochem Cell Biol. 2011;43(8):1114-1121.
29. Lanzavecchia A. Antigen uptake and accumulation in antigen-specific B cells. Immunol Rev. 1987;99:39-51.
30. Le Roux D, Le Bon A, Dumas A, et al. Antigen stored in dendritic cells after macropinocytosis is released unprocessed from late endosomes to target B cells. Blood. 2012;119(1):95-105.
31. Dasgupta S, Repesse Y, Bayry J, et al. VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors. Blood. 2007;109(2):610-612.
32. Saenko EL, Scandella D. The acidic region of the factor VIII light chain and the C2 domain together form the high affinity binding site for von Willebrand factor. J Biol Chem. 1997;272(29):18007-18014.
33. Shima M, Scandella D, Yoshioka A, et al. A factor VIII neutralizing monoclonal antibody and a human inhibitor alloantibody recognizing epitopes in the C2 domain inhibit factor VIII binding to von Willebrand factor and to phosphatidylserine. Thromb Haemost. 1993;69(3):240-246.
34. Jacquemin MG, Desqueper BG, Benhida A, et al. Mechanism and kinetics of factor VIII inactivation: study with an IgG4 monoclonal antibody derived from a hemophilia A patient with inhibitor. Blood. 1998;92(2):496-506.
35. Tuddenham EG, Lane RS, Rotblat F, et al. Response to infusions of polyelectrolyte fractionated human factor VIII concentrate in human haemophilia A and von Willebrand's disease. Br J Haematol. 1982;52(2):259-267.
36. Mei B, Pan C, Jiang H, et al. Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment. Blood. 2010;116(2):270- 279.
37. van Schooten CJ, Shahbazi S, Groot E, et al. Macrophages contribute to the cellular uptake of von Willebrand factor and factor VIII in vivo. Blood. 2008;112(5):1704-1712.
38. Navarrete A, Dasgupta S, Delignat S, et al. Splenic marginal zone antigen-presenting cells are critical for the primary allo-immune response to therapeutic factor VIII in hemophilia A. J Thromb Haemost. 2009;7(11):1816-1823.
39. Lenting PJ, van Schooten CJ, Denis CV. Clearance mechanisms of von Willebrand factor and factor VIII. J Thromb Haemost. 2007;5(7):1353-1360.
40. Rastegarlari G, Pegon JN, Casari C, et al. Macrophage LRP1 contributes to the clearance of von Willebrand factor. Blood. 2012;119(2):2126-2132.
41. Reth M. Antigen receptors on B lymphocytes. Annu Rev Immunol. 1992;10:97-121.
42. Lollar P, Parker CG. Stoichiometry of the porcine factor VIII-von Willebrand factor association. J Biol Chem. 1987;262(36):17572-17576.
43. Reding MT, Wu H, Krampf M, et al. CD4+ T cell response to factor VIII in hemophilia A, acquired hemophilia, and healthy subjects. Thromb Haemost. 1999;82(2):509-515.
44. Qian J, Borovok M, Bi L, Kazazian HH Jr, Hoyer LW. Inhibitor antibody development and T cell response to human factor VIII in murine hemophilia A. Thromb Haemost. 1999;81(2):240-244.
45. Steinitz KN, van Helden PM, Binder B, et al. CD4+ T-cell epitopes associated with antibody responses after intravenously and subcutaneously applied human FVIII in humanized hemophilic E17 HLA-DRB1*1501 mice. Blood. 2012;119(17):4073-4082.
46. Benjamin DC, Berzofsky JA, East IJ, et al. The antigenic structure of proteins: a reappraisal. Ann Rev Immunol. 1984;2:67-101.
47. Vanderlugt CL, Miller SD. Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat Rev Immunol. 2002;2(2):85-95.